Canaccord Genuity Group Issues Positive Forecast for AxoGen (NASDAQ:AXGN) Stock Price

AxoGen (NASDAQ:AXGN) had its price objective raised by equities researchers at Canaccord Genuity Group from $55.00 to $60.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Canaccord Genuity Group‘s price target indicates a potential upside of 20.89% from the stock’s current price.

AXGN has been the subject of a number of other research reports. Morgan Stanley downgraded shares of AxoGen to a “hold” rating in a report on Tuesday, September 29th. Leerink Partners lifted their price target on shares of AxoGen from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Thursday. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research note on Thursday, July 30th. Wells Fargo & Company increased their price target on shares of AxoGen from $48.00 to $56.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Bank of America assumed coverage on AxoGen in a report on Monday, October 12th. They set a “buy” rating and a $52.00 target price for the company. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.92.

AxoGen Stock Up 0.8%

Shares of AXGN traded up $0.38 during midday trading on Thursday, reaching $49.63. The stock had a trading volume of 2,280,852 shares, compared to its average volume of 1,202,146. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -72.98 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The company’s fifty day simple moving average is $42.78 and its two-hundred day simple moving average is $39.28. AxoGen has a 1-year low of $21.68 and a 1-year high of $52.91.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $73.18 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Equities research analysts expect that AxoGen will post -0.44 earnings per share for the current year.

Insider Activity

In related news, Director Joseph Tyndall sold 3,500 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director directly owned 10,650 shares in the company, valued at $529,305. This trade represents a 24.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,503 shares of company stock valued at $4,656,947. Company insiders own 2.44% of the company’s stock.

Institutional Trading of AxoGen

Hedge funds have recently made changes to their positions in the stock. Nykredit A S purchased a new position in AxoGen in the second quarter valued at about $30,000. KBC Group NV acquired a new stake in shares of AxoGen in the first quarter worth $41,000. Sterling Capital Management LLC lifted its position in AxoGen by 858.9% during the 3rd quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 1,589 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in AxoGen by 16.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock valued at $118,000 after purchasing an additional 409 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AxoGen in the second quarter valued at approximately $203,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded estimates. AxoGen reported third-quarter adjusted earnings of $0.21 per share, ahead of the $0.13–$0.14 consensus range, while revenue of $75.83 million surpassed the $73.18 million estimate. Earnings also improved from $0.12 per share a year earlier. AxoGen Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects at least 29% annual revenue growth, or approximately $290 million, reinforcing the view that demand is outpacing prior expectations. AxoGen Q3 2026 Earnings and Guidance
• Positive Sentiment: Analysts raised their targets and maintained bullish ratings. Truist lifted its target from $53 to $60 while keeping a Buy rating. Wells Fargo raised its target from $48 to $56 with an Overweight rating, and HC Wainwright increased its target from $53 to $56 while maintaining Buy ratings.
• Positive Sentiment: Options activity reflected increased bullish interest. Investors purchased 9,886 call options, nearly 11 times the typical daily volume, although options activity can also reflect short-term speculation.
• Neutral Sentiment: AxoGen’s strong year-to-date performance has prompted discussion about whether much of the improved outlook is already reflected in the stock’s valuation.
• Negative Sentiment: Despite the earnings beat, the company continues to report a negative net margin and negative return on equity, leaving profitability and execution risks for investors to monitor.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.